Trial Profile
An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs CYAD 01 (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Liver metastases
- Focus Adverse reactions
- Acronyms LINK
- Sponsors Celyad Oncology
- 27 Feb 2024 Status changed from active, no longer recruiting to discontinued.
- 18 Jun 2020 Planned End Date changed from 15 Dec 2019 to 15 Dec 2020.
- 07 May 2019 Planned End Date changed from 1 Jul 2020 to 15 Dec 2019.